Glutamine: fructose-6-phosphate amidotransferase (GFAT): homology modelling and designing of new inhibitors using pharmacophore and docking based hierarchical virtual screening protocol

SAR and QSAR in Environmental Research

Volumn 24, Issue 9, 2013, Pages 733-752

  Vyas, B ^a   Silakari, O ^a   Singh Bahia, M ^a   Singh, B ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

diabetic complications; GFAT; hierarchical virtual screening; homology modelling; induced fit docking; pharmacophore

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; FRUCTOSE; PHARMACODYNAMICS;

AMIDOTRANSFERASES; DIABETIC COMPLICATION; FRUCTOSE 6 PHOSPHATES; GLUTAMINE: FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; HIERARCHICAL VIRTUAL SCREENING; HOMOLOGY MODELING; INDUCED FIT; INDUCED-FIT DOCKING; PHARMACOPHORES; VIRTUAL SCREENING;

MOLECULES;

MAMMALIA; RUMEX;

ANTIDIABETIC AGENT; ENZYME INHIBITOR; GLUTAMINE FRUCTOSE 6 PHOSPHATE AMINOTRANSFERASE;

ANIMAL; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; ENZYME ACTIVE SITE; HUMAN; ISOLATION AND PURIFICATION; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN CONFORMATION;

ANIMALS; CATALYTIC DOMAIN; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; GLUTAMINE-FRUCTOSE-6-PHOSPHATE TRANSAMINASE (ISOMERIZING); HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION;

EID: 84882583402     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2013.797493     Document Type: Article

References (34)

1. Diabetes Control and Complications Trial Research (DCCTR) Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993), pp. 977-986.
2. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352 (1998), pp. 837-853.
3. Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 414: 813 - 820.
4. Brownlee, M. 2005. The pathobiology of diabetic complications: A unifying mechanism. Diabetes, 54: 1615 - 1625.
5. Gabbay, K.H., Merola, L.O. and Field, R.A. 1996. Sorbitol pathway: Presence in nerve and cord with substrate accumulation in diabetes. Science, 151: 209 - 210.
6. McLellan, A.C., Thornalley, P.J., Benn, J. and Sonksen, P.H. 1994. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin. Sci. (Lond), 87: 21 - 29.
7. Koya, D. and King, G.L. 1998. Protein kinase C activation and the development of diabetic complications. Diabetes, 47: 859 - 866.
8. Marshall, S., Bacote, V. and Traxinger, R.R. 1991. Discovery of a metabolic pathway mediating glucose induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol. Chem., 266: 4706 - 4712.
9. Kolm-Litty, V., Sauer, U., Nerlich, A., Lehmann, R. and Schleicher, E.D. 1998. High glucose induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest., 101: 160 - 169.
10. Du, X.L., Edelstein, D., Rossetti, L., Fantus, I.G., Goldberg, H., Ziyadeh, F., Wu, J. and Brownlee, M. 2000. Hyperglycemia induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl Acad. Sci. USA, 97: 12222 - 12226.
11. Hawkins, M., Barzilai, N., Liu, R., Hu, M., Chen, W. and Rossetti, L. 1997. Role of the glucosamine pathway in fat induced insulin resistance. J. Clin. Invest., 99: 2173 - 2182.
12. McKnight, G.L., Mudri, S.L., Mathewes, S.L., Traxinger, R.R., Marshall, S., Sheppard, P.O. and O'Hara, P.J. 1992. Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase. J. Biol. Chem., 267: 25208 - 25212.
13. Niimi, M., Ogawara, T., Yamashita, T., Yamamoto, Y., Ueyama, A., Kambe, T., Okamoto, T., Ban, T., Tamanoi, H., Ozaki, K., Fujiwara, T., Fukui, H., Takahashi, E., Kyushiki, H. and Tanigami, A.J. 2001. Identification of GFAT1-L, a novel splice variant of human glutamine:fructose-6-phosphate amidotransferase (GFAT1) that is expressed abundantly in skeletal muscle. J. Hum. Genet., 46: 566 - 571.
14. Oki, T., Yamazaki, K., Kuromitsu, J., Okada, M. and Tanaka, I. 1999. CDNA cloning and mapping of a novel subtype of glutamine:fructose-6-phosphate amidotransferase (GFAT2) in human and mouse. Genomics, 57: 227 - 234.
15. Whitmore, T.E., Mudri, S.L. and McKnight, G.L. 1995. Physical mapping of the human glutamine:fructose-6-phosphate amidotransferase gene (GFPT) to chromosome 2p13. Genomics, 26: 422 - 423.
16. Zhou, J., Neidigh, J.L., Espinosa, R., LeBeau, M.M. and McClain, D.A. 1995. Human glutamine:fructose-6-phosphate amidotransferase: Characterization of mRNA and chromosomal assignment to 2p13. Hum. Genet., 96: 99 - 101.
17. DeHaven, J.E., Robinson, K.A., Nelson, B.A. and Buse, M.G. 2001. A novel variant of glutamine:fructose-6-phosphate amidotransferase-1 (GFAT1) mRNA is selectively expressed in striated muscle. Diabetes, 50: 2419 - 2424.
18. Nakaishi, Y., Bando, M., Shimizu, H., Watanabe, K., Goto, F., Tsuge, H., Kondo, K. and Komatsu, M. 2009. Structural analysis of human glutamine:fructose-6-phosphate amidotransferase, a key regulator in type 2 diabetes. FEBS Lett., 583: 163 - 167.
19. Chou, K.C. 2004. Molecular therapeutic target for type-2 diabetes. J. Proteome Res., 3: 1284 - 1288.
20. Qian, Y., Ahmad, M., Chen, S., Gillespie, P., Le, N., Mennona, F., Mischke, S., So, S.S., Wang, H., Burghardt, C., Tannu, S., Conde-Knape, K., Kochan, J. and Bolin, D. 2011. Discovery of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors. Bioorg. Med. Chem. Lett., 21: 6264 - 6269.
21. Walker, B., Brown, M.F., Lynas, J.F., Martin, S.L., McDowell, A., Badet, B. and Hill, A.J. 2000. Inhibition of Escherichia coli glucosamine synthetase by novel electrophilic analogues of glutamine-comparison with 6-diazo-5-oxo-norleucine. Bioorg. Med. Chem. Lett., 10: 2795 - 2798.
22. Auvin, S., Cochet, O., Kucharczyk, N., Le Goffic, F. and Badet, B. 1991. Synthesis and evaluation of inhibitors for Escherichia coli glucosamine-6-phosphate synthase. Bioorg. Chem., 19: 143 - 151.
23. Bobzin, S.C., Yang, S. and Kasten, T.P. 2000. Application of liquid chromatography-nuclear magnetic resonance spectroscopy to the identification of natural products. J. Chromatogr. B. Biomed. Sci. Appl., 748: 259 - 267.
24. Dixon, S.L., Smondyrev, A.M., Knoll, E.H., Rao, S.N., Shaw, D.E. and Friesner, R.A. 2006. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des., 20: 647 - 671.
25. Kaur, M., Bahia, M.S. and Silakari, O. 2012. Exploring the role of water molecules for docking and receptor guided 3D-QSAR analysis of naphthyridine derivatives as spleen tyrosine kinase (Syk) inhibitors. J. Chem. Inf. Model., 52: 2619 - 2630.
26. Silakari, O., Chand, S. and Bahia, M.S. 2012. Structural basis of amino pyrimidine derivatives for inhibitory activity of PKC-θ: 3D-QSAR and molecular docking studies. Mol. Inform., 31: 659 - 668.
27. Verma, J., Khedkar, V.M. and Coutinho, E.C. 2010. 3D-QSAR in drug design: A review. Curr. Top. Med. Chem., 10: 95 - 115.
28. Golbraikh, A. and Tropsha, A. 2002. Beware of q2!. J. Mol. Graph. Model., 20: 269 - 276.
29. Kaur, M., Kumari, A., Bahia, M.S. and Silakari, O. 2013. Designing of new multi-targeted inhibitors of spleen tyrosine kinase (Syk) and zeta-associated protein of 70 kDa (ZAP-70) using hierarchical virtual screening protocol. J. Mol. Graph. Model., 39: 165 - 175.
30. Zhang, S., Golbraikh, A., Oloff, S., Kohn, H. and Tropsha, A. 2006. A novel automated lazy learning QSAR (ALL-QSAR) approach: Method development, applications, and virtual screening of chemical databases using validated ALL-QSAR models. J. Chem. Inf. Model., 46: 1984 - 1995.
31. Isupov, M.N., Obmolova, G., Butterworth, S., Badet-Denisot, M., Badet, B., Polikarpov, I., Littlechild, J.A. and Teplyakov, A. 1996. Substrate binding is required for assembly of the active conformation of the catalytic site in Ntn amidotransferases: Evidence from the 1.8 A crystal structure of the glutaminase domain of glucosamine 6-phosphate synthase. Structure, 4: 801 - 810.
32. Sherman, W., Day, T., Jacobson, M.P., Friesner, R.A. and Farid, R. 2006. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem., 49: 534 - 553.
33. Sherman, W., Beard, H.S. and Farid, R. 2006. Use of an induced fit receptor structure in virtual screening. Chem. Biol. Drug Des., 67: 83 - 84.
34. Saxena, A.K. and Roy, K.K. 2012. Hierarchical virtual screening: Identification of potential high-affinity and selective β(3)-adrenergic receptor agonists. SAR QSAR Environ. Res., 23: 389 - 407.